A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of Weight-Reducing and Prevention of Weight Regain Effects and Safety in Obese Patients With or Without Comorbidities.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of Weight-Reducing and Prevention of Weight Regain Effects and Safety in Obese Patients With or Without Comorbidities.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 May 2009

At a glance

  • Drugs Rimonabant (Primary)
  • Indications Obesity
  • Focus Registrational; Therapeutic Use
  • Acronyms RIO-North America
  • Sponsors Sanofi-Synthelabo
  • Most Recent Events

    • 12 May 2009 Primary endpoint identified as body weight as reported by ClinicalTrials.gov.
    • 14 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top